Evidence map›Paper›PMID 41200698›Full record

ArticleJournal of AIDS and HIV treatment2025

Beyond Viral Suppression: Navigating Structural Barriers, Aging and Frailty, Drug Resistance, Therapeutic Innovations, and Reproductive Health Challenges in the Global HIV/AIDS Epidemic.

Ahizechukwu C Eke, Uzoamaka A Eke

Abstract read
In one paragraph

Article in Journal of AIDS and HIV treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ahizechukwu C EkeDivision of Maternal Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Uzoamaka A EkeDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Maryland, USA.

Funding

Integrated proteomic and metabolomic biomarker profiling for understanding metabolic syndrome in pregnant women living with HIV on Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir (TLD)DP1HD115433 · NICHD · JOHNS HOPKINS UNIVERSITY · PI AHIZECHUKWU C. EKE · 2024 to 2026
$1.7M
Understanding Medication Adherence Benchmarks, Safety and Pharmacometrics of Novel Antiretrovirals in Pregnant Women Living with HIV.K23HD104517 · NICHD · JOHNS HOPKINS UNIVERSITY · PI EKE, AHIZECHUKWU C. · 2020 to 2024
$857k
NICHD NIH HHS DP1 HD115433NICHD NIH HHS K23 HD104517
6 · The paper itself

Abstract

HIV programs worldwide have achieved remarkable gains toward viral suppression, transforming HIV from a fatal illness into a chronic condition for many. Despite these successes, a substantial proportion of people living with HIV (PLWH) continue to face poor health outcomes that extend well beyond viral control. Persistent social determinants of health and structural barriers, including poverty, stigma, discrimination, and disrupted health systems, limit access to prevention, treatment, and retention in care. At the same time, demographic shifts have created new challenges, with more than half of PLWH in high-income countries now aged ≥50 years, facing accelerated aging, multi-morbidity, and neurocognitive decline. Emerging drug resistance, both pretreatment and transmitted, threatens the durability of existing regimens, particularly in low- and middle-income countries where routine resistance testing remains limited. In reproductive health, women of childbearing age remain disproportionately affected, with ongoing complexities around antiretroviral selection, adverse pregnancy outcomes, and the long-term health of HIV-exposed but uninfected (HEU) infants. This narrative review synthesizes evidence from peer-reviewed studies, global guidelines, and major clinical trials published up until September 2025 to explore these converging issues. By highlighting gaps and opportunities across aging, structural barriers to care, social determinants of health, therapeutic innovation, and reproductive health, we underscore the need for inclusive, multidisciplinary, and evidence-based HIV care models for the next decade.

Indexed as

AIDSCabotegravirDolutegravirFrailtyHIVHIV and AgingLenacapavirMetabolomicsPregnancyProteomicsTherapeutic innovationTranscriptomics

Identifiers

PMID41200698
PMCPMC12587877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.